These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35085216)

  • 1. Two new pneumococcal vaccines - Prevnar 20 and Vaxneuvance.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):188-190. PubMed ID: 35085216
    [No Abstract]   [Full Text] [Related]  

  • 2. Two New Pneumococcal Vaccines-Prevnar 20 and Vaxneuvance.
    JAMA; 2021 Dec; 326(24):2521-2522. PubMed ID: 34962532
    [No Abstract]   [Full Text] [Related]  

  • 3. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Pneumococcal Vaccines for Prevention of Invasive Pneumococcal Disease in Adult Patients With Inflammatory Bowel Disease.
    Crosby S; Schuh MJ; Becker M; Ivanov M; Caldera F; Farraye FA
    Inflamm Bowel Dis; 2023 Apr; 29(4):661-664. PubMed ID: 35830419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Tomczyk S; Bennett NM; Stoecker C; Gierke R; Moore MR; Whitney CG; Hadler S; Pilishvili T;
    MMWR Morb Mortal Wkly Rep; 2014 Sep; 63(37):822-5. PubMed ID: 25233284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult immunization.
    Med Lett Drugs Ther; 2022 Oct; 64(1661):161-168. PubMed ID: 36206162
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.
    Greenberg RN; Gurtman A; Frenck RW; Strout C; Jansen KU; Trammel J; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2014 Apr; 32(20):2364-74. PubMed ID: 24606865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M; Bennett NM; Gierke R; Almendares O; Moore MR; Whitney CG; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):944-7. PubMed ID: 26334788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
    Esposito S; Principi N
    Future Microbiol; 2019 Jul; 14():921-923. PubMed ID: 31373218
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction.
    Njuma Libwea J; Gröndahl-Yli-Hannuksela K; Kobela M; Toropainen M; Nyholm O; Ndombo PK; Koulla-Shiro S; Nohynek H; Nuorti JP; Vuopio J; Palmu AA
    Int J Infect Dis; 2020 Sep; 98():113-120. PubMed ID: 32562849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization for Streptococcus pneumoniae infections in high-risk children.
    Committee On Infectious Diseases
    Pediatrics; 2014 Dec; 134(6):1230-3. PubMed ID: 25422018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
    Gladstone RA; Jefferies JM; Faust SN; Clarke SC
    Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.